Trials not for MS, but something to keep in mind.
Synta launches human trials for anti-inflammatory drug
Synta Pharmaceuticals Corp. has launched two new midstage human clinical trials to test an anti-inflammatory drug.
The Lexington, Mass.-based private company said it had began dosing patients in two separate Phase II trials regarding the compound apilimod mesylate. One trial will focus on rheumatoid arthritis and the other will target common variable immunodeficiency, a condition that can lead to gastrointestinal complications.
Apilimod mesylate is designed to inhibit a family of proteins that cause inflammations in conditions including Crohn's disease, psoriasis, rheumatoid arthritis, multiple sclerosis and gastrointestinal problems from common variable immunodeficiency.
Source: Boston Business Journal © 2006 American City Business Journals, Inc. and its licensors. All rights reserved.